Core Viewpoint - MaxCyte and Ori Biotech have formed a strategic collaboration to enhance the efficiency, scalability, and productivity of cell therapy manufacturing by integrating their respective platforms, ExPERT™ and IRO® [1][4]. Group 1: Collaboration Details - The collaboration combines MaxCyte's ExPERT™ platform, known for its efficient transfection capabilities, with Ori's IRO platform, which automates cell therapy manufacturing [2][3]. - The initial evaluation will focus on optimizing the yield and manufacturing timelines of MaxCyte-engineered primary T cells using CD19 CAR expression via CRISPR knock-in [2][3]. Group 2: Technological Integration - MaxCyte's technology provides flexibility and efficiency in transfecting cells at a clinical scale, integrating well with various processes in cell therapy workflows [3]. - Ori's IRO platform enhances cell culture efficiency through automated fluid handling and customizable mixing, contributing to improved scalability [3]. Group 3: Leadership Insights - MaxCyte's CEO expressed excitement about the collaboration, emphasizing the commitment to improving manufacturing processes and accelerating the availability of cell therapies [4]. - Ori's CEO highlighted the partnership as a demonstration of their dedication to providing scalable solutions that address challenges in cell and gene therapy manufacturing [4]. Group 4: Industry Impact - The collaboration aims to enable therapy developers to adopt integrated solutions, thereby accelerating the transition from research to commercialization and increasing patient access to next-generation treatments [4].

Core Insights - Kytopen Corp. and Bio-Techne Corporation have announced a partnership to enhance gene delivery solutions for advanced cell therapies, focusing on the integration of their respective technologies [1][5] - The collaboration aims to streamline workflows for genome engineering of immune cell therapies, expediting their clinical advancement and manufacturing [1][5] Company Overview - Kytopen is a leader in non-viral, continuous flow cellular engineering technologies, headquartered in Cambridge, Massachusetts, and is known for maximizing yields and delivering hundreds of billions of engineered cells rapidly [6] - Bio-Techne is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [7] Technology Highlights - The TcBuster™ system allows for the simultaneous delivery of multiple genes with high editing efficiency, offering advantages over traditional lentivirus-based methods [2][5] - Flowfect® technology combines mechanical, electrical, and chemical forces to enhance transfection efficiency and cell health, enabling the processing of billions of cells in minutes [2][5] Collaboration Details - The partnership will leverage the TcBuster™ GMP non-viral genome engineering system and the Flowfect Tx™ GMP cellular engineering platform to create a non-viral gene-editing workflow suitable for various immune cell types [1][3] - Data from the collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, showcasing the advancements made through this partnership [3][5]